davita ebitda ahead consensu driven improv
ancillari segment despit lower sequenti non-acquir treatment growth
revenu estim howev delta entir driven
declin davita rx busi wind
follow outsiz spend improv medicar price better y/i
result ancillari intern busi declin acquisit cost
calcimimet headwind includ migrat out-of-network contract in-
network drive net commerci price labor cost increas
follow slow organ treatment growth non-acquir
treatment growth expect rang vs
addit management size impact latest iter dialysi legisl
propos california headwind ultim pass detail
provid move part behind estim small part due lack
specif includ bill around exactli legisl might implement
continu work optum obtain ftc approv dmg
transact management note review transact delay recent
govern shutdown provid definit time-frame complet
side continu work toward complet howev odd increas
transact slip point
estim price target oper incom estim go
primarili reflect lower expect non-
acquir treatment growth chang price target base
ebitda-nci estim pro-forma sale dmg
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight like risk/reward head
particularli given expect
sale dmg expect materi share
repo next year pro-forma dmg sale
share trade signific discount
histor trade rang
estim revis higher multipl
expand ebitda
commerci mix pressur increas drive mix
increment result revis
ebitda estim proce sale dmg
less expect result lower share repo
forward ebitda multipl contract
pro-forma sale
incom y/i q/q na na na na na na na patient bad incom y/i y/i expens incom y/i tax share barclay davita inc
patrick feeley steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli
indirectli relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
procedur pleas
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
